Immunovant Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Valuation Ratios
P/B Ratio4.107.605.531.364.01
Price/Tangible Book4.107.605.531.364.01
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-0.62%-0.53%-0.51%-0.36%-0.44%
Return on Assets (ROA)-0.38%-0.32%-0.28%-0.21%-0.26%
Return on Capital Employed (ROCE)-0.62%-0.44%-0.57%-0.33%-0.28%
Leverage & Solvency Ratios
Debt/Equity0.000.000.000.010.01
Liquidity Ratios
Current Ratio11.1613.709.3411.5221.79
Quick Ratio10.4213.188.7211.3821.38
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield-0.14%-0.06%-0.11%-0.24%-0.07%
FCF Yield-0.13%-0.05%-0.09%-0.17%-0.05%
Buyback Yield-0.10%-0.12%-0.12%-0.25%-1.03%